Abstract
The overall aim of this chapter is to review the literature regarding the experiences of primary caregivers (i.e., family members who care for a person with Alzheimer disease) and decisions about drug therapy. Specifically, the purpose is to describe the experience of acetylcholinesterase inhibitor (AChEI) therapy of primary caregivers of persons with Alzheimer disease (AD), outline the inherent ethical issues that are part of drug therapy decisions, and suggest areas for future, empirical research.